Taysha Gene Therapies (TSHA) EBITDA Margin (2023 - 2025)
Taysha Gene Therapies (TSHA) posted EBITDA Margin of 2334.98% for Q4 2025, down 73.34% sequentially from 1347.08% in Q2 2025, and down 134923.0% YoY from N/an in Q4 2024.
Taysha Gene Therapies (TSHA) EBITDA Margin (2023 - 2025) Analysis & Trends
Taysha Gene Therapies has reported EBITDA Margin for 3 years, with the latest figure at 2334.98% in Q4 2025.
- Quarterly EBITDA Margin fell 134923.0% year-over-year to 2334.98% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 4145.18% (down 291941.0% YoY) and the FY2025 annual result came in at 2009.05%, down 91150.0% from the prior year.
- EBITDA Margin retreated to 2334.98% in Q4 2025 per TSHA's latest filing, from 1347.08% in the prior quarter.
- Over five years, EBITDA Margin peaked at 342.39% in Q3 2023 and troughed at 2334.98% in Q4 2025.
- A 3-year average of 1072.44% and a median of 976.37% in 2023 frame the typical range for EBITDA Margin.
- The widest YoY moves for EBITDA Margin: up 56830 bps in 2025, down 134923 bps in 2025.
- Over 3 years, EBITDA Margin stood at 450.78% in 2023, then sank by 119 bps to 985.76% in 2024, then tumbled by 137 bps to 2334.98% in 2025.
- According to Business Quant data, EBITDA Margin over the past three periods registered 2334.98%, 1347.08%, and 930.54% for Q4 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2,334.98% |
| Jun 30, 2025 | -1,347.08% |
| Mar 31, 2025 | -930.54% |
| Dec 31, 2024 | -985.76% |
| Sep 30, 2024 | -1,448.43% |
| Jun 30, 2024 | -1,915.38% |
| Mar 31, 2024 | -713.28% |
| Dec 31, 2023 | -450.78% |
| Sep 30, 2023 | -342.39% |
| Jun 30, 2023 | -976.37% |
| Mar 31, 2023 | -351.87% |